We appreciate the authors’ thoughtful letter and their emphasis on the growing body of evidence linking sodium-glucose cotransporter 2 inhibitors (SGLT2is) treatment to enhanced erythropoiesis and iron metabolism [1]. As outlined in our recent review [2], the therapeutic benefits of SGLT2is extend well beyond glycemic control, encompassing cardio-renal protection, cognitive effects, and emerging implicantions in andrology. The additional perspectives offered on iron availability, erythropoiesis, and cardiovascular outcomes further enrich this expanding field of research and deserve close consideration.
